BioNTech announced its financial results for the last year and the final quarter through a statement.
According to the announcement, the company’s net profit in 2023 decreased by 90% compared to the previous year, reaching 930.3 million euros. BioNTech had reported a profit of 9.434 billion euros in 2022.
The company’s revenues decreased by 78% in the last year compared to 2022, dropping to 3.819 billion euros. BioNTech had achieved a revenue of 17.31 billion euros in 2022.
The company aims for this year’s revenues to be between 2.5 billion and 3.1 billion euros, depending on regulatory developments and the purchase of the COVID-19 vaccine.
The R&D expenditures of the company are estimated to be between 2.4 billion and 2.6 billion euros this year.
Meanwhile, BioNTech’s net profit in the fourth quarter of last year decreased by 80% compared to the same period of the previous year, reaching 457.9 million euros.
Prof. Dr. Uğur Şahin, the CEO and co-founder of BioNTech, stated that the company maintained its leading position in the COVID-19 vaccine market last year and strengthened its core competencies by entering into various partnerships in the field of oncology, making significant clinical progress. He expressed, “Our goal is to obtain approval for 10 products in oncology by 2030 and thus improve treatment options for patients worldwide.”
source: aa.com.tr/ prepared by Melisa Beğiç